Chongqing Taiji Industry (Group) Co., Ltd.SSE: 600129

Announcement on Passing of the Generic Drug Consistency Evaluation for Digoxin Injection

· Issued by Chongqing Taiji Industry (Group) Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

Chongqing Taiji Industry (Group) Co., Ltd. announced that its subsidiary, Southwest Pharmaceutical Co., Ltd., has received approval for Digoxin Injection after passing the consistency evaluation for generic drugs. The approval indicates that the drug meets the required quality and efficacy standards for generic medications. Digoxin Injection is used for treating heart failure and controlling heart rates in patients with certain heart conditions. The company highlighted the potential for increased market competitiveness and support in medical procurement due to this approval.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Passing of the Generic Drug Consistency Evaluation for Digoxin Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Chongqing Taiji Industry (Group) Co., Ltd. on 6ix

Earlier from Chongqing Taiji Industry (Group)

Later from Chongqing Taiji Industry (Group)

All Chongqing Taiji Industry (Group) news releases